Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021

Patients with invasive fungal disease (IFD) are at significant risk of morbidity and mortality. A productive partnership between patients, their carers/families, and the multidisciplinary team managing the infection and any underlying conditions, is essential. Sharing information and addressing knowledge gaps are required to ensure those at risk of IFD avoid infection, while those with suspected or confirmed infection optimise their therapy and avoid toxicities. This new addition to the Australian and New Zealand consensus guidelines for the management of IFD and antifungal use in the haematology/oncology setting outlines the key information needs of patients and their carers/families. It specifically addresses risk factor reduction, antifungal agents and adherence, and the risks and benefits of complementary and alternative therapies. Knowledge gaps are also identified to help inform the future research agenda.

[1]  Jessie Zhao,et al.  Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021 , 2021, Internal medicine journal.

[2]  Brendan R. Jackson,et al.  Public Awareness of Invasive Fungal Diseases — United States, 2019 , 2020, MMWR. Morbidity and mortality weekly report.

[3]  D. Roder,et al.  Patterns of health service utilisation among the Australian population with cancer compared with the general population. , 2019, Australian health review : a publication of the Australian Hospital Association.

[4]  C. Solano,et al.  Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[5]  R. Avery,et al.  Strategies for safe living following solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice , 2019, Clinical transplantation.

[6]  V. White,et al.  "An Ambition to Make People Feel at Home" or "The Emperor's New Clothes"? Professional stakeholder views of wellness centres in cancer care. , 2019, European journal of cancer care.

[7]  K. Berger,et al.  Improving quality of antifungal use through antifungal stewardship interventions , 2019, Infection.

[8]  B. Salehi,et al.  Novel Therapies for Biofilm-Based Candida spp. Infections. , 2019, Advances in experimental medicine and biology.

[9]  P. Ljungman,et al.  European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. , 2018, The Journal of antimicrobial chemotherapy.

[10]  A. DeMichele,et al.  Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Berta,et al.  Antifungal activity of essential oils against azole-resistant and azole-susceptible vaginal Candida glabrata strains. , 2018, Canadian journal of microbiology.

[12]  C. Beigelman-Aubry,et al.  Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  M. Aydoğdu,et al.  Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient. , 2017, Journal de mycologie medicale.

[14]  M. Karagas,et al.  Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation , 2017, Journal of the American Academy of Dermatology.

[15]  R. L. de Souza,et al.  SACCHAROMYCES CEREVISIAE FUNGEMIA IN A PEDIATRIC PATIENT AFTER TREATMENT WITH PROBIOTICS , 2017, Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo.

[16]  B. Décaudin,et al.  Factors relevant to medication non-adherence in kidney transplant: a systematic review , 2017, International Journal of Clinical Pharmacy.

[17]  L. Pagano,et al.  Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. , 2017, Blood reviews.

[18]  T. Perl,et al.  Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. , 2017, Diagnostic microbiology and infectious disease.

[19]  C. Selinger,et al.  Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions , 2017, Expert review of gastroenterology & hepatology.

[20]  J. George,et al.  Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products , 2017, Expert review of clinical pharmacology.

[21]  C. Murray,et al.  In Vitro activity of Manuka Honey and polyhexamethylene biguanide on filamentous fungi and toxicity to human cell lines , 2016, Medical mycology.

[22]  M. Klokker,et al.  Upper Respiratory Infections and Barotrauma Among Commercial Pilots. , 2017, Aerospace medicine and human performance.

[23]  Z. Kusic,et al.  Use of Alternative and Complementary Medicine in Patients with Malignant Diseases in High-Volume Cancer Center and Future Aspects , 2016, Acta clinica Croatica.

[24]  G. Berta,et al.  Sensitivity of Candida albicans to essential oils: are they an alternative to antifungal agents? , 2016, Journal of applied microbiology.

[25]  J. Huebner,et al.  Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care , 2016, Medical Oncology.

[26]  A. Hochhaus,et al.  Case report: false positive elevated serum‐galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements , 2016, Clinical case reports.

[27]  R. Mody,et al.  Epidemiology of Histoplasmosis Outbreaks, United States, 1938–2013 , 2016, Emerging infectious diseases.

[28]  J. Bryant,et al.  To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. , 2016, Critical reviews in oncology/hematology.

[29]  S. Patole,et al.  Probiotic supplementation for preventing invasive fungal infections in preterm neonates – a systematic review and meta‐analysis , 2015, Mycoses.

[30]  W Buylaert,et al.  Communication in healthcare: a narrative review of the literature and practical recommendations , 2015, International journal of clinical practice.

[31]  A. Stolbach,et al.  A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products , 2015, Journal of Medical Toxicology.

[32]  E. G. Silva,et al.  A multispecies probiotic reduces oral Candida colonization in denture wearers. , 2015, Journal of prosthodontics : official journal of the American College of Prosthodontists.

[33]  Christina C. Chang,et al.  Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014 , 2014, Internal medicine journal.

[34]  M. Hoenigl,et al.  Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. , 2014, International journal of antimicrobial agents.

[35]  R. Gorton,et al.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. , 2014, The Journal of antimicrobial chemotherapy.

[36]  Anne M. Williams,et al.  An Oasis in the Hospital , 2014, Journal of holistic nursing : official journal of the American Holistic Nurses' Association.

[37]  T. Ng,et al.  Case report: Enteral nutritional supplement as a likely cause of false-positive galactomannan testing , 2013, Medical mycology case reports.

[38]  J. Schellens,et al.  Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. , 2013, Cancer treatment reviews.

[39]  M. Bougnoux,et al.  Naturotherapy as a potential source of mould infections in patients with haematological malignancies. , 2013, The Journal of hospital infection.

[40]  Russell E. Lewis,et al.  A Risk Prediction Score for Invasive Mold Disease in Patients with Hematological Malignancies , 2013, PloS one.

[41]  Mike Thomas,et al.  Managing patients with stable respiratory disease planning air travel: a primary care summary of the British Thoracic Society recommendations , 2013, Primary care respiratory journal : journal of the General Practice Airways Group.

[42]  Jeffrey M Schussler,et al.  Drug-induced QT interval prolongation: mechanisms and clinical management , 2012, Therapeutic advances in drug safety.

[43]  J. Kendrick,et al.  Vomiting of oral medications by pediatric patients: survey of medication redosing practices. , 2012, The Canadian journal of hospital pharmacy.

[44]  M. Hoenigl,et al.  Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. , 2012, International journal of antimicrobial agents.

[45]  K. Hood,et al.  The use of the Medication Event Monitoring System (MEMS) for assessing medication adherence for chronic conditions: use and results from a 12 month trial of patients in remission with ulcerative colitis (UC) , 2011, Trials.

[46]  A. Simonds,et al.  Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations , 2011, Thorax.

[47]  R. Igreja.  Infectious Diseases Associated with Caves , 2011, Wilderness & environmental medicine.

[48]  J. Canhoto,et al.  Chemical composition and antifungal activity of the essential oils of Lavandula viridis L'Her. , 2011, Journal of medical microbiology.

[49]  G. Maschmeyer.  The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections. , 2009, The Journal of antimicrobial chemotherapy.

[50]  J. Sivik,et al.  Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up , 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[51]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  D. Cescon,et al.  Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  K. Kwon,et al.  Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers , 2006, European Journal of Clinical Pharmacology.

[54]  J. Hafid,et al.  Molecular confirmation of an absidiomycosis following treatment with a probiotic supplement in a child with leukemia , 2006 .

[55]  J. Galgiani,et al.  An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. , 2005, The Journal of infectious diseases.

[56]  I. Bali,et al.  The effect of high altitude commercial air travel on oxygen saturation , 2005, Anaesthesia.

[57]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[59]  R. Courtney,et al.  Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults , 2003, Antimicrobial Agents and Chemotherapy.

[60]  G. Y. Chang,et al.  Sino-cerebral aspergillosis due to chronic herbal medicine use. , 2003, QJM : monthly journal of the Association of Physicians.

[61]  K. Song,et al.  PCR-aided diagnosis of fungal chorioretinitis following ingestion of traditional Chinese medication. , 2002, Retina.

[62]  F. Derouin,et al.  Fungal Contamination of Food in Hematology Units , 2000, Journal of Clinical Microbiology.

[63]  S. Singletary,et al.  Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Boeckh,et al.  Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  R. Locksley,et al.  Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. , 1988, Chest.

[66]  F. Torti,et al.  Possible Risk of Invasive Pulmonary Aspergillosis with Marijuana Use during Chemotherapy for Small Cell Lung Cancer , 1986, Drug intelligence & clinical pharmacy.

[67]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.

[68]  C. W. Emmons.  Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). , 1955, American journal of hygiene.